Preliminary Real-World Outcomes of Adjuvant Immunotherapy in Resected Esophageal Cancer: A Retrospective Study from Taiwan
AI did not demonstrate a significant survival advantage compared to AC, even in patients meeting CheckMate 577 criteria or those with ypN+ status. Identifying the optimal adjuvant treatment for esophageal cancer remains a challenging and evolving issue.
Authors
- Ling‐I Chien (ORCID: https://orcid.org/0009-0006-4745-7114)
- Yi‐Chen Yeh (ORCID: https://orcid.org/0000-0002-6442-4967)
- Chia Liu (ORCID: https://orcid.org/0009-0003-0284-3570)
- Po‐Kuei Hsu (ORCID: https://orcid.org/0000-0003-1790-0227)
- Chien‐Sheng Huang (ORCID: https://orcid.org/0000-0002-3206-2869)
- Han‐Shui Hsu (ORCID: https://orcid.org/0000-0002-4584-1626)
Institutions
- National Yang Ming Chiao Tung University (TW)
- Taipei Veterans General Hospital (TW)
Publication Details
- Journal
- Journal of Chest Surgery
- Published
- 2025-07-01
- DOI
- https://doi.org/10.5090/jcs.25.024
- Citations
- 2
- Primary Topic
- Esophageal Cancer Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 4.01